IPO - HELIUS MEDICAL TECHNOLOGIES, INC.

Form Type: 424B4

Filing Date: 2025-06-06

Corporate Action: Ipo

Type: New

Accession Number: 000110465925056970

Filing Summary: Helius Medical Technologies, Inc. is offering 2,627,050 shares of common stock as part of a public offering. This includes pre-funded warrants for an additional 141,550 shares and common warrants for 2,768,600 shares. Each common warrant has an initial exercise price of $7.3575 per share and is immediately exercisable for a duration of 2.5 years. The combined public offering price for each share and common warrant is set at $3.27. The offering also mentions a zero cash exercise option for warrants, indicating that holders can exchange warrants for shares without additional cash payment. Key developments include stockholder approvals for a reverse stock split, increasing authorized shares to 800 million, and proposed financing for issuing additional shares. Helius has engaged Maxim Group LLC as the exclusive placement agent for this public offering. The last reported sale price of Helius common stock on June 4, 2025, was $3.27. Recent compliance issues with Nasdaq concerning bid price and equity requirements necessitate strict adherence to capital raising measures and corporate governance following the offering.

Form Type: CORRESP

Filing Date: 2025-06-03

Corporate Action: Ipo

Type: Update

Accession Number: 000110465925056021

Filing Summary: Helius Medical Technologies, Inc. has submitted a request for the withdrawal of its acceleration request regarding its Registration Statement on Form S-1, originally filed on May 28, 2025. The acceleration was meant for the Registration Statement to be declared effective on May 29, 2025. However, the placement agent, Maxim Group LLC, has announced that they are no longer pursuing this request. Instead, they are requesting that the effective date of the Registration Statement be accelerated to June 4, 2025, at 5:00 PM, Eastern Time, or as soon as practicable thereafter. Maxim asserts awareness of its obligations under the Securities Act related to this offering.

Form Type: CORRESP

Filing Date: 2025-05-28

Corporate Action: Ipo

Type: New

Accession Number: 000110465925053348

Filing Summary: Helius Medical Technologies, Inc. submitted a request for acceleration of the effectiveness of its Registration Statement on Form S-1 (File No. 333-287572). The company has requested that the Registration Statement be declared effective on May 29, 2025, at 5:00 P.M. Eastern Time, or as soon as practicable thereafter. N. Danny Shulman of Honigman LLP has been authorized to make this request on behalf of the company. The document establishes communication with the SEC and includes contact details for confirmation regarding the effectiveness of the Registration Statement.

Form Type: S-1

Filing Date: 2025-05-23

Corporate Action: Ipo

Type: New

Accession Number: 000110465925052494

Filing Summary: On May 23, 2025, Helius Medical Technologies, Inc. filed a Form S-1 with the SEC related to a public offering of 3,448,275 shares of Class A common stock and accompanying common warrants. The registration includes up to 7,068,963 shares potentially issuable upon exercise of pre-funded and common warrants. A reverse stock split approved by stockholders was also finalized, converting shares at a ratio of 1-for-15. The company has received various approvals concerning stock splits, authorized shares, and compensation plans. The process is part of preparing for a public offering following compliance with Nasdaq’s minimum listing requirements. The offering price and terms are to be determined based on market conditions at pricing. The proceeds will support ongoing developments and are expected to have implications on share ownership and market activities.

Form Type: DRS

Filing Date: 2025-04-15

Corporate Action: Ipo

Type: New

Accession Number: 000110465925035130

Filing Summary: Helius Medical Technologies, Inc. has filed a draft registration statement (DRS) with the SEC for an initial public offering (IPO) of its securities. This includes shares of Class A common stock and warrants. The registration indicates a focus on offering pre-funded warrants to certain purchasers to circumvent ownership limitations. The last reported sale price of Helius' common stock prior to the offering was $0.30 per share. The document also outlines the implications of being classified as a smaller reporting company, with associated reporting benefits. Additionally, it details compliance issues with Nasdaq, including a failure to meet minimum bid price and stockholders’ equity requirements, and outlines the timelines for regaining compliance. The registration is filed as a confidential document and does not constitute a public offer yet.

Form Type: DRSLTR

Filing Date: 2025-04-15

Corporate Action: Ipo

Type: New

Accession Number: 000110465925035135

Filing Summary: Helius Medical Technologies, Inc. submitted a draft registration statement on Form S-1 for non-public review by the U.S. Securities and Exchange Commission (SEC). This submission allows for an initial public offering (IPO) process. The company plans to publicly file the registration statement at least two business days prior to the effective date. Contact details for the company representatives are provided for further inquiries.